Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

PathGroup Expands Operations with Proscia Concentriq Dx

By Author Proscia | March 1, 2023

PathGroup, one of the largest providers of anatomic, clinical, digital, and molecular pathology services in the United States, is expanding its operations with Proscia’s Concentriq® Dx* to further enhance the delivery of faster, higher quality results for millions of patients, helping to better inform treatment decisions.

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency. 

Our website uses cookies. By using this site, you agree to its use of cookies.